Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
“We are working to advance the AG10 clinical development program,” said Neil Kumar PhD, chief executive officer of Eidos. “The Phase 1 data demonstrated that AG10 was well tolerated at blood concentrations resulting in near-complete TTR stabilization in healthy volunteers. We are announcing the results from the Phase 2 study in ATTR cardiomyopathy patients at the 2018 American Heart Association Annual Scientific Sessions on
Recent Achievements and Upcoming Milestones
- Eidos presented Phase 1 data at the 2018 Annual Scientific Meeting of the
Heart Failure Society of America, demonstrating that AG10 was well tolerated and establishing clinical proof-of-concept in healthy adult volunteers.
- The U.
S Food & Drug Administrationgranted Orphan Drug Designation to AG10 for the treatment of ATTR.
The European Medicines Agencyadopted a positive opinion for the designation of AG10 as an orphan medicinal product for the treatment of ATTR.
The Journal of Medicinal Chemistrypublished the design and preclinical characterization of AG10, demonstrating that AG10’s potentially superior stabilizing activity is driven by the unique ability to mimic the disease-protective T119M mutation and its selectivity for TTR.
- The Phase 2 study of AG10 in ATTR cardiomyopathy (ATTR-CM) wild-type and mutant patients with symptomatic heart failure (NYHA Class II-III) concluded and eligible subjects entered a long term, open label extension study.
- Eidos will present the Phase 2 data for AG10 in ATTR-CM at the Annual Scientific Sessions of the
American Heart Association(AHA) in a late-breaking Featured Science oral presentation on November 10, 2018at 10am EST. Eidos will also host a conference call and webcast on November 12, 2018at 8am ESTto discuss the results of the Phase 2 trial. Details for the conference call can be found at www.eidostx.com.
Financial Results for the Third Quarter 2018
Cash and cash equivalents totaled
Research and development expenses were
General and administrative expenses were
Net loss for the quarter ended September 30, 2018 was
AG10 is an orally administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. AG10 has completed a Phase 2 clinical trial in patients with ATTR cardiomyopathy and symptomatic heart failure. Results from this trial will be presented on
AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a “rescue mutation” because it has been shown to prevent ATTR in individuals also carrying a pathogenic, or disease-causing, mutation in their other copy of the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the “super-stabilizing” properties of this rescue mutation that have been well described.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act. All statements other than statements of historical facts, including the statements about future clinical milestones of AG10, including the completion of our ongoing Phase 2 clinical trial and availability of top-line data therefrom, the initiation of Phase 3 clinical trials, the timing of these events, the indications we intend to pursue, the potential benefits available to us from orphan drug designations for AG10, and our possible clinical or other business strategies, are forward-looking statements. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. These forward-looking statements are based on our management’s current beliefs and assumptions about future events and on information currently available to management.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: our limited operating history and historical losses, our liquidity to fund the development of our other product candidates through current and future milestones, our ability to raise additional funding to complete the development and any commercialization of our product candidates, our dependence on the success of our lead product candidate, AG10, results from our clinical trials and pre-clinical studies and those of third parties working in the same area as our product candidate and our dependence on third parties in connection with our manufacturing, clinical trials and pre-clinical studies. Additional risks and uncertainties that could affect our future results are included in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our quarterly report on Form 10-Q for the quarter ended September 30, 2018 to be filed with the
Condensed Statements of Operations
(In thousands, except share and per share data)
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Research and development||$||7,931||$||2,283||$||21,362||$||5,583|
|General and administrative||2,619||490||6,656||1,322|
|Total operating expenses||10,550||2,773||28,018||6,905|
|Loss from operations||(10,550||)||(2,773||)||(28,018||)||(6,905||)|
|Other income (expense), net||374||-||(1,681||)||75|
|Loss on extinguishment of debt||-||-||(6,677||)||-|
|Net loss per share:||$||(0.29||)||$||(0.74||)||$||(2.28||)||$||(1.95||)|
|Weighted-average shares used in computing net loss|
|per share basic and diluted||35,591,518||3,752,883||15,976,228||3,504,790|
|* Includes stock-based compensation as follows|
|Research and development||$||(187||)||$||26||$||2,016||$||100|
|General and administrative||443||1||627||2|
|Total stock-based compensation expense||$||256||$||27||$||2,643||$||102|
Condensed Balance Sheets
(In thousands, except share data)
|September 30,||December 31,|
|Related party receivable||29||67|
|Prepaid expenses and other current assets||3,248||484|
|Total current assets||169,845||6,048|
|Property and equipment, net||218||114|
|Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)|
|Related party payable||206||372|
|Accrued expenses and other current liabilities||3,427||1,300|
|Total current liabilities||6,050||2,238|
|Redeemable convertible preferred stock||-||17,028|
|Stockholders’ equity (deficit):|
|Additional paid-in capital||214,690||1,332|
|Total stockholders’ equity (deficit)||163,819||(13,196||)|
|Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)||$||170,226||$||6,343|
Source: Eidos Therapeutics, Inc.